Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Barr To Pursue Generic Version of Neupogen Under Agreement With Pliva

This article was originally published in The Pink Sheet Daily

Executive Summary

Barr agreement with Pliva marks the generic drug marketer's second move into generic biologics, with the company aiming to become an early leader in the field. Barr will be responsible for regulatory work to establish a pathway for approval of G-CSF.

You may also be interested in...



Barr Gains European Foothold Through $2.2 Bil. Pliva Acquisition

Pliva’s supervisory board accepts Barr’s bid despite several rivals vying for the Croatian generics firm.

Barr Gains European Foothold Through $2.2 Bil. Pliva Acquisition

Pliva’s supervisory board accepts Barr’s bid despite several rivals vying for the Croatian generics firm.

Generic Biologics Timing Depends On FDA Commissioner, Barr Says

The products could be on the market within three years if an FDA commissioner of former chief McClellan's "disposition" is confirmed, CEO Downey says. The process could take longer if the confirmed commissioner is more "reticent to change."

Topics

UsernamePublicRestriction

Register

PS061874

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel